My understanding is the route we have taken is slower but more prudent to check all the fda requirment before you start a registration trial ie those animals studies in AR have only just been finshed this year. Also the new MTD gives us a better shot but again they did not like the time wasted. As far as I could tell much centred around wanting this drug in registration trials yesterday not next year and management did not listen to them. You be the judge on their motives for selling.
- Forums
- ASX - By Stock
- Ann: Kazia Annual Report
My understanding is the route we have taken is slower but more...
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online